Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HAE vs UFPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HAE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

HAE Overall Winner 6-Pillar Tally: HAE 4 – 1 UFPT (1 Tie) Matrix Metrics: HAE 6 – 4 UFPT

As of Nov 16, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HAE carries a Unified Composite Score of 51.4/100 (HOLD) at $121.34 (22.9x Forward P/E, 18.8% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).

  • Technical & Structure Timing Caution: HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.0); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HAE vs UFPT
HAE NYSE Head-to-Head Winner
Haemonetics Corporation
Surgical & Medical Instruments & Apparatus
$121.34
-1.3% 1D
Market Cap $5.6B
TTM Revenue $1.38B
Forward P/E 22.9x
Beta / 30D Vol 0.27β · 32% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 53.0 Fund 47.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 59
RSI-14: 59.0 · SMA20: $120.43 · SMA50: $113.71
UFPT NASDAQ
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17

6-Pillar Scorecard Institutional Category Breakdown (HAE 4 – 1 UFPT)

Columns: Metric · HAE · UFPT
1. Valuation Multiples HAE
Forward P/E 22.9x 24.7x
Trailing P/E 54.4x 31.2x
PEG Ratio 1.92x 3.80x
EV / Revenue 4.0x 3.6x
2. Growth & Scale UFPT
Revenue Growth (YoY) +9.3% +11.6%
Earnings Growth (YoY) +23.5% +25.1%
TTM Revenue (USD) $1.38B $650M
Market Cap $5.6B $2.4B
3. Profitability & Quality HAE
Gross Margin 59.8% 28.9%
Operating Margin 18.8% 15.4%
Net Profit Margin 7.5% 11.8%
Return on Equity (ROE) 11.9% 17.2%
4. Balance Sheet & Cash Flow HAE
Cash Generation (TTM) $364M EBITDA $120M EBITDA
Cash Flow Margin 26.3% EBITDA Mgn 18.5% EBITDA Mgn
Net Cash / Leverage $19.74 Book/Sh · 11.9% ROE $62.70 Book/Sh · 17.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 32.7% (2nd %ile) 42.3% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat HAE
OpEx & R&D Intensity 41.0% of Rev ($567M) 13.5% of Rev ($88M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HAE (6) vs UFPT (4)
Institutional Metric HAE UFPT Criterion Row Edge
Market Capitalization
Scale
$5.6B $2.4B Larger Scale HAE
Trailing P/E Ratio
Valuation
54.4x 31.2x Lower Multiple UFPT
Forward P/E Ratio
Valuation
22.9x 24.7x Lower Multiple HAE
Revenue Growth (YoY)
Growth
+9.3% +11.6% Higher Growth UFPT
Operating Margin (TTM)
Profitability
18.8% 15.4% Higher Margin HAE
Net Profit Margin
Profitability
7.5% 11.8% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
11.9% 17.2% Higher ROE UFPT
52-Week Range Position
Momentum
87% ($51–$132) 74% ($174–$342) Stronger Trend HAE
Beta / 30D Volatility
Risk Regime
0.27β · 32% Vol 1.64β · 77% Vol Lower Realized Risk HAE
Unified Institutional Score
Composite Signal
51.4 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite HAE
Trailing 12M Revenue (USD)
Operating Scale
$1.38B $650M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.8% 28.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.92x PEG · 4.0x EV/Rev 3.80x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$364M EBITDA ($19.74 Book/Sh · 11.9% ROE) $120M EBITDA ($62.70 Book/Sh · 17.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HAE +0.23 pp
HAE: +2.59% · UFPT: +2.36%
3M Horizon HAE +20.87 pp
HAE: +15.95% · UFPT: -4.92%
6M Horizon HAE +74.4 pp
HAE: +111.84% · UFPT: +37.44%
1Y Horizon HAE +36.75 pp
HAE: +64.17% · UFPT: +27.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HAE vs UFPT. Trailing 12-month operating profitability (HAE 18.8% vs UFPT 15.4%) and valuation multiples (HAE 22.9x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.

HAE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.38B
Gross Margin59.8%
Op. Margin18.8%
ROE / Fwd P/E11.9% · 22.9x
UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HAE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.7%
IV Percentile 2nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HAE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HAE Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $5.6B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment 41.0% of Rev ($567M)
90D Engineering Disclosures 0 Published
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published

Investor FAQ HAE vs UFPT Key Questions & Quantitative Answers

As of Nov 16, 2026, Haemonetics Corporation (HAE) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). HAE carries a Unified Composite Score of 51.4/100 (HOLD) at $121.34 (22.9x Forward P/E, 18.8% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Technical & Structure Timing Caution: HAE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.0); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: HAE posts +9.3% YoY revenue growth and +23.5% YoY earnings growth on $1.38B TTM revenue (59.8% gross margin, 18.8% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, HAE generates $1.38B in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, HAE deploys 41.0% of Rev ($567M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.

HAE screens cheaper on headline valuation multiples. HAE trades at 22.9x Forward P/E, 54.4x Trailing P/E, 1.92x PEG, and 4.0x EV/Revenue (26.3% EBITDA margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HAE (11.9% ROE) versus UFPT (17.2% ROE) capital efficiency.

In options market volatility and institutional positioning, HAE carries 32.7% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 32% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.